A Phase II clinical study evaluating the efficacy and safety of BB-1701 in patients with HER2-expressing locally advanced or metastatic breast cancer
Latest Information Update: 28 Jul 2026
At a glance
- Drugs BB 1701 (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Bliss Biopharmaceutical
Most Recent Events
- 02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
- 28 Aug 2025 New trial record